Use of eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia

Abstract

Eltrombopag has been used in Immune Thrombocytopenic Purpura (ITP) and also found effective in Aplastic Anemia (AA) recently. We prospectively analyzed 50 patients at Dhaka Shishu Hospital in Dhaka from January 2019 to December 2023. We included patients with severe AA who were refractory to at least one course of immunosuppressive therapy and persistent/chronic ITP who have received at least one previous treatment for ITP. Responses to Eltrombopag in our population were comparable to real-world experiences while tolerable hepatotoxicity and GI issues were notable. We found Eltrombopag to be a safe and efficacious agent for treating patients with ITP and AA.